Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 15/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14832794 | 0.78 | RXFP1 (0.69) | KAT2BRXFP1L3MBTL1ALDH1A1HTT | |
| SCHEMBL496605 | 0.77 | RXFP1 (0.55) | RXFP1L3MBTL1 | |
| SCHEMBL31146696 | 0.75 | RXFP1 (1.00) | KAT2BRXFP1L3MBTL1HTTMEN1 | |
| SCHEMBL5524673 | 0.75 | RXFP1 (1.00) | KAT2BRXFP1L3MBTL1HTTMEN1 | |
| SCHEMBL497285 | 0.72 | NPC1 (0.69) | RXFP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL15426081 | 0.72 | KAT2B (0.52) | KAT2BALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22323375 | 0.71 | ALDH1A1 (0.41) | KAT2BRXFP1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL496713 | 0.71 | RXFP1 (0.59) | RXFP1L3MBTL1HTTMEN1KMT2A | |
| SCHEMBL2830794 | 0.70 | RXFP1 (0.62) | RXFP1L3MBTL1ALDH1A1HTTMEN1 | |
| SCHEMBL7479574 | 0.69 | RXFP1 (0.56) | RXFP1L3MBTL1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | KAT2B 2437/4885RXFP1 2969/4885L3MBTL1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.